Evidence map›Paper›PMID 30624689›Full record

ArticleJournal of the National Cancer Institute2019

COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials.

Kathryn T Hall, Julie E Buring, Kenneth J Mukamal, M Vinayaga Moorthy, Peter M Wayne, Ted J Kaptchuk, Elisabeth M Battinelli, Paul M Ridker, Howard D Sesso, Stephanie J Weinstein and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Catechol-O-Methyltransferase and Cardiovascular Disease: MESA.Journal of the American Heart Association · 2019
    Observational
  16. Drug-Placebo Additivity in Randomized Clinical Trials.Clinical pharmacology and therapeutics · 2019
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Kathryn T HallDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Julie E BuringDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Kenneth J MukamalDivision of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA.
M Vinayaga MoorthyDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Peter M WayneDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Ted J KaptchukDivision of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA.
Elisabeth M BattinelliCardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Paul M RidkerDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Howard D SessoDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Nancy R CookDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Daniel I ChasmanDivisions of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USDivision of Cancer Epidemiology and GeneticsNational Cancer Institute · US

Funding

Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) StudyZIACP010195 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$22.5M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
Women's Health Study: Infrastructure support for continued cohort follow-upU01CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2019 to 2023
$4.0M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
Mentoring and Research in Placebo Studies, Asian Medicine, and CAMK24AT004095 · NCCIH · HARVARD MEDICAL SCHOOL · PI KAPTCHUK, TED · 2007 to 2016
$1.4M
The Women's Health Study: Addition of New Data to Maximize its Research ImpactRC1HL099355 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2009 to 2010
$992k
Epidemiological, pharmacogenomic and clinical impact of catechol-O-methyltransferase on cardiovascular diseaseK01HL130625 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HALL, KATHRYN TAYO · 2016 to 2021
$921k
Mentoring and research in mind-body and integrative therapiesK24AT009282 · NCCIH · BRIGHAM AND WOMEN'S HOSPITAL · PI WAYNE, PETER MICHAEL · 2017 to 2021
$834k
NCCIH NIH HHS K24 AT004095NCCIH NIH HHS K24 AT009282NCI NIH HHS HHSN261201500005CNCI NIH HHS R01 CA047988NCI NIH HHS U01 CA182913NCI NIH HHS UM1 CA182913NHLBI NIH HHS K01 HL130625NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355
6 · The paper itself

Abstract

backgroundVitamins are among the most frequently used supplements (48% of US adults). However, little is known about contributions of genetic variation to their efficacy and safety. Multiple pathways link catechol-O-methyltransferase (COMT) to the vitamin E supplement, alpha-tocopherol, and cancer.

methodsHere we determined if COMT exerted pharmacogenetic effects on cancer prevention in two randomized trials of alpha-tocopherol supplementation. Pharmacogenetic effects of common COMT rs4680 (val158met), which encodes a nonsynonymous valine-to-methionine substitution, were examined in the trial plus a 10-year post-trial follow-up (overall) period of The Women's Genome Health Study (WGHS, N = 23 294), a 10-year alpha-tocopherol and aspirin trial with 10 years post-trial follow-up. Results were validated in a case/control (N = 2396/2235) subset of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC, N = 29 133). The primary outcome was total cancers. Rates of cancer types prevalent in women (colorectal, breast, lung, uterine, and lymphoma/leukemia) were also examined. All statistical tests were two-sided.

resultsRandom-effects meta-analysis of rs4680 genotype strata, in WGHS and ATBC overall periods, revealed differential alpha-tocopherol effects compared with placebo: met/met (hazard ratio [HR] = 0.88; 95% confidence interval [CI] = 0.80 to 0.97; P = .01), val/met (HR = 0.99; 95% CI = 0.92 to 1.06; P = .74), and val/val (HR = 1.18; 95% CI = 1.06 to 1.31; P = .002) with a statistically significant COMT by alpha-tocopherol interaction (Pinteraction <.001). Timing of effects differed, with stronger effects in WGHS trial and ATBC post-trial.

conclusionPharmacogenetic analysis of COMT and cancer prevention in two large randomized trials revealed statistically significant COMT by alpha-tocopherol interaction, such that alpha-tocopherol was beneficial among rs4680 met-allele (28.0%), but not val-allele (22.8%) homozygotes. These effects indicate the need for additional studies of genetic variation as a determinant of the benefits and possible harms of over-the-counter supplements, like alpha-tocopherol, used for health promotion.

Indexed as

Genetic Association StudiesAllelesalpha-Tocopherolbeta CaroteneCatechol O-MethyltransferaseDietary SupplementsFemaleGenotypeHumansMaleNeoplasmsPharmacogenomic TestingRandomized Controlled Trials as Topicalpha-Tocopherolbeta CaroteneCatechol O-MethyltransferaseCOMT protein, human

Identifiers

PMID30624689
PMCPMC6624170
OpenAlexW2908640065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.